NeoGenomics to Present Eight Abstracts at ASCO 2026 Meeting (ir.neogenomics.com)

• Eight abstracts to be presented at ASCO 2026, including posters and online publications.
• Covers topics: MRD (RaDaR ST), NGS coverage disparities, AML genomics, breast cancer MRD (SURVIVE studies), liquid vs tissue concordance, fusion-driven sarcomas.
• New biomarkers for ADC, BiTE, bispecific, radioligand therapies: B7-H3, CD137, EZH2, PRMT5.
• Development of low-sample-input AML MRD flow assay with higher sensitivity.
• Collaboration with MD Anderson on ctDNA dynamics in colorectal cancer.

"NeoGenomics announced it will present eight scientific abstracts at the 2026 ASCO Annual Meeting. The abstracts cover MRD detection, NGS testing coverage gaps, genomic profiling in hematologic malignancies, and liquid biopsy concordance. The company highlighted new biomarkers (B7-H3, CD137, EZH2, PRMT5) for biopharma partners and a low-sample-input AML MRD flow assay under development. Collaborations include MD Anderson Cancer Center for ctDNA detection in colorectal cancer."